The Food and Drug Administration Friday issued final guidance clarifying that an organization may operate both a compounding pharmacy and outsourcing facility at the same address or general location if they are completely segregated by clearly identified boundaries, for example permanent physical barriers such as walls or doors that are locked. If the pharmacy is not completely segregated from the outsourcing facility, FDA would generally consider the pharmacy part of the outsourcing facility and subject to Section 503B of the Federal Food, Drug and Cosmetic Act and current good manufacturing practice, the agency said. Both compounders also should clearly label their drug products as compounded at a pharmacy or outpatient facility, FDA said. The Drug Quality and Security Act of 2013 created the outsourcing facility category.

Related News Articles

Headline
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Headline
The AHA and Federation of American Hospitals today urged the U.S. Supreme Court to review a federal appeals court decision that allows False Claims Act…
Headline
The House Energy and Commerce Health Subcommittee today held a hearing on legislation to roll back changes to the Affordable Care Act by the Trump…
Headline
The AHA yesterday urged Sens. Bill Cassidy, R-La., and Dick Durbin, D-Ill., not to re-introduce legislation that would establish rehabilitation innovation…
Headline
The AHA today expressed support for the Resident Physician Shortage Reduction Act, legislation that would add 15,000 Medicare-funded residency positions over…
Headline
Reps.